antazoline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antihistaminics or local vasoconstrictors, antazoline derivatives 224 91-75-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • antazoline mesylate
  • antazoline sulfate
  • antazoline
  • phenazoline
  • antazoline phosphate
  • antazoline hydrochloride
  • antazoline HCl
An ethylenediamine derivative with histamine H1 antagonistic and sedative properties. Antazoline antagonizes histamine H1 receptor and prevents the typical allergic symptoms caused by histamine activities on capillaries, skin, mucous membranes, and gastrointestinal and bronchial smooth muscles. These histamine activities include vasodilation, bronchoconstriction, increased vascular permeability, pain, itching, and spasmodic contractions of gastrointestinal smooth muscles. Antazoline is used to provide symptomatic relieve of allergic symptoms.
  • Molecular weight: 265.36
  • Formula: C17H19N3
  • CLOGP: 4.11
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 27.63
  • ALOGS: -3.37
  • ROTB: 5
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O
0.30 g P

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 3.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 19.67 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.29 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 0.66 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.306 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.074 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 18.197 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 39.174 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 22.070 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 41.790 % High 1
herg hERG pIC50 5.891 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 50.816 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 163.682 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 26.680 % High 1
kinase-safety-class ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,MAP3K7,MAPK10,MAPK7,NTRK2,PDK4,PDPK1,PIK3CB,PIM2,PRKDC,STK33,TEK,TTK 26
kinase-selectivity-class AXL,GRK2 2
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.991 High 1
mh-clint Mouse hepatocyte intrinsic clearance 238.781 High 1
mppb Mouse plasma protein binding (% unbound) 26.010 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 3.258 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 62.780 % High 1
rh-clint Rat hepatocyte intrinsic clearance 270.396 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 70.100 % High 1
rppb Rat plasma protein binding (% unbound) 41.670 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 877.001 uM High 1

Approvals:

DateAgencyCompanyOrphan
April 30, 1990 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R01AC04 RESPIRATORY SYSTEM
NASAL PREPARATIONS
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
Antiallergic agents, excl. corticosteroids
ATC R06AX05 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Other antihistamines for systemic use
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018926 Anti-Allergic Agents
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:37955 H<small><sub>1</sub></small>-receptor antagonist
CHEBI has role CHEBI:48873 cholinergic antagonist
CHEBI has role CHEBI:77715 nasal decongestant
CHEBI has role CHEBI:67079 anti-inflammatory agent

Related Drugs by ATC class:

R01AC Antiallergic agents, excl. corticosteroids 7 drugs
azelastinecromoglicic acidlevocabastinenedocromilolopatadinespaglumic acidthonzylamine
R06AX Other antihistamines for systemic use 26 drugs
acrivastineastemizoleazatadineazelastinebamipinebilastinecyproheptadinedeptropinedesloratadineebastineepinastinefexofenadine show all 26 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Dermatographic urticaria indication 7632005 DOID:743
Vasomotor rhinitis indication 8229003 DOID:4730
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Nasal congestion indication 68235000
Red eye indication 75705005
Sneezing indication 76067001
Urticaria indication 126485001
Itching of skin indication 418363000
Allergic conjunctivitis indication 473460002 DOID:11204
Anaphylaxis Adjunct indication
Ocular Itching indication
Ocular hypertension contraindication 4210003 DOID:9282
Peptic ulcer contraindication 13200003 DOID:750
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Chronic idiopathic constipation contraindication 82934008
Eye infection contraindication 128351009
Bladder outflow obstruction contraindication 236645006
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Injury of eye region contraindication 282752000
Angle-closure glaucoma contraindication 392291006 DOID:13550




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.35 Basic
pKa2 3.96 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST CHEMBL CHEMBL
Histamine H1 receptor GPCR Kd 7.14 CHEMBL

External reference:

IDSource
4019615 VUID
N0000147709 NUI
D02950 KEGG_DRUG
3131-32-6 SECONDARY_CAS_RN
24359-81-7 SECONDARY_CAS_RN
2680384 RXNORM
C0003143 UMLSCUI
CHEBI:84115 CHEBI
CHEMBL1305 ChEMBL_ID
DB08799 DRUGBANK_ID
CHEMBL1200550 ChEMBL_ID
D000865 MESH_DESCRIPTOR_UI
2200 PUBCHEM_CID
7116 IUPHAR_LIGAND_ID
1142 INN_ID
154-68-7 SECONDARY_CAS_RN
DHA8014SS1 UNII
4205 MMSL
CHEMBL1256819 ChEMBL_ID
2508-72-7 SECONDARY_CAS_RN
4019060 VANDF
4019150 VANDF
4019615 VANDF
003378 NDDF
003379 NDDF
003380 NDDF
003724 NDDF
005437 NDDF
373544004 SNOMEDCT_US
387061002 SNOMEDCT_US
396006001 SNOMEDCT_US
7816005 SNOMEDCT_US
85408000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nestabs ONE HUMAN PRESCRIPTION DRUG LABEL 10 50967-410 CAPSULE, GELATIN COATED 225 mg ORAL unapproved drug other 12 sections